Riding on the back of evolving technological environment, the global healthcare and pharmaceutical industry is now surmounting new acmes. The growth of the respective sector is further filliped by the increasing number of health related issues surfacing on account of changing lifestyle and incessantly evolving surroundings. To cater to the necessity of better healthcare options and the unmet needs within the some of the underlying segments, related companies are coming up with novel and improved diagnostic technologies and treatment therapies, especially in the field of breast cancer treatment. ‘Cancer’ is the result of any mutation or abnormal changes in the genes which are responsible for regulating the growth of cells and keeping them healthy. The tumor formed due to cancer can be either ‘benign’ (not dangerous) or ‘malignant’ (potentially dangerous). ‘Breast cancer’ is a malignant tumor that has developed from cells in the breast. Typically breast cancer either begins in the cells of the lobules (milk-producing glands), or the ducts (the passages that drain milk from the lobules to the nipple). The stages of breast cancer are crucial as they only determine the type of treatment method and the extent to which the disease can be cured. On the diagnosis front, mammography is believed to diagnose 85% to 90% of breast cancers in women over 50, and is capable of discovering a lesion one to four years before a lump can be felt. In case of patients with dense breast tissue, breast implants or patients who are breastfeeding, mammography cannot produce clear images; therefore, in such cases, ultrasound or MRI is recommended. Biopsy is used for the diagnosis of breast cancer once a lesion is detected in screening. For treatment of breast cancer, the first method to be used is surgical, followed by hormone therapy, chemo therapy or radiation therapy. After lung cancer, breast cancer is the 2nd most prevalent type of cancer and 5th most common cause of cancer deaths on global scale. Over one million new cases of breast cancer are diagnosed every year world over. The present report offers a comprehensive analysis of the global breast cancer diagnosis and treatment market with focus on regions like the US, India and Brazil including the revenue build of two major drugs in the coming years. Furthermore, market dynamics such as the industry trends and development, the underlying growth drivers and major issues faced by the industry are elicited. On the contention front, the market is personified by the intense competition in terms of research and development of novel therapeutic molecules, diagnostics technology application and pricing of the product. The leading players operating in the industry include Hologic, J&J and Siemens AG which are also profiled in this report.

1. Global Breast Cancer Market
---------------------------------------------
2013
View Report Details

2. Executive Summary
Riding on the back of evolving technological environment, the global healthcare and pharmaceutical industry is now surmounting
new acmes. The growth of the respective sector is further filliped by the increasing number of health related issues surfacing on
account of changing lifestyle and incessantly evolving surroundings. To cater to the necessity of better healthcare options and the
unmet needs within the some of the underlying segments, related companies are coming up with novel and improved diagnostic
technologies and treatment therapies, especially in the field of breast cancer treatment.
„Cancer‟ is the result of any mutation or abnormal changes in the genes which are responsible for regulating the growth of cells
and keeping them healthy. The tumor formed due to cancer can be either „benign‟ (not dangerous) or „malignant‟ (potentially
dangerous). „Breast cancer‟ is a malignant tumor that has developed from cells in the breast. Typically breast cancer either begins
in the cells of the lobules (milk-producing glands), or the ducts (the passages that drain milk from the lobules to the nipple).
The stages of breast cancer are crucial as they only determine the type of treatment method and the extent to which the disease
can be cured. On the diagnosis front, mammography is believed to diagnose 85% to 90% of breast cancers in women over 50,
and is capable of discovering a lesion one to four years before a lump can be felt. In case of patients with dense breast tissue,
breast implants or patients who are breastfeeding, mammography cannot produce clear images; therefore, in such cases,
ultrasound or MRI is recommended. Biopsy is used for the diagnosis of breast cancer once a lesion is detected in screening. For
treatment of breast cancer, the first method to be used is surgical, followed by hormone therapy, chemo therapy or radiation
therapy.
After lung cancer, breast cancer is the 2nd most prevalent type of cancer and 5th most common cause of cancer deaths on global
scale. Over one million new cases of breast cancer are diagnosed every year world over.
The present report offers a comprehensive analysis of the global breast cancer diagnosis and treatment market with focus on
regions like the US, India and Brazil including the revenue build of two major drugs in the coming years. Furthermore, market
dynamics such as the industry trends and development, the underlying growth drivers and major issues faced by the industry are
elicited. On the contention front, the market is personified by the intense competition in terms of research and development of
novel therapeutic molecules, diagnostics technology application and pricing of the product. The leading players operating in the
industry include Hologic, J&J and Siemens AG which are also profiled in this report.
View Report Details

3. Any mutation or abnormal change in the genes accountable for regulating the growth of cells and keeping
them healthy causes ‘Cancer’. ‘Breast cancer’ defines a malignant tumor that has developed from cells in
the breast.
 The oncology sales were worth US$........billion in 2011 which is
poised to reach US$.......... billion by 2014.
As of 2011, the breast cancer therapeutics market in the major
countries including the US, the UK, Germany, France, Italy, Spain,
Japan, Brazil, Russia, India, and China, collectively was worth
US$......... billion, growing at a CAGR of …………..% since 2000. The
revenues generation by the respective industry is likely to reach
US$........... billion by 2020.
Industry Trends and Developments
-Successive Clinical Trials and Product Development
Growth Drivers
-Increasing Prevalence of Cancer
-Increasing Use of Tobacco and Alcohol
-Expanding Obese Population
-Rising Demand for Better Healthcare Options
-Growing Female Population (+45 Years)
-Higher Spending on Medicines 36
Challenges
-Rising Costs of Treatment
-Stringent Regulatory Measures
-Adverse Effects of the Treatment
-Mounting Price Pressure
Global Oncology Sales (2009-2014E)
Breast Cancer Therapeutics Market (2011 and 2020E)
2009 2010 2011 2012E 2013E 2014E
US$Billion
2011 2020E
US$Billion

4. An estimated …… breast cancer deaths; …….. women, …….men are likely to occur in 2013. Breast cancer
ranks second as a cause of cancer death in women (after lung cancer)….
The US breast imaging systems market generated revenues worth
US$........... billion in 2011 while it is estimated to reach US$...... billion
in 2016, growing at a CAGR of ……..% over the cited period. The very
growth is anticipated to be driven by the X-ray, mammography, breast
ultrasound, breast MRI and molecular breast imaging techniques.
The Brazilian breast cancer imaging market is likely to grow from
US$............million in 2011 to US$......... million by 2018, at a compound
annual growth rate of ………% over the period cited.
The Indian breast cancer imaging market is anticipated to grow from
US$........... million in 2011 to US$...................million by 2018 at a
CAGR of ……%.
India’s Breast Screening Market (2011 and 2018E)Brazil’s Breast Cancer Imaging Market (2011 and 2018E)
)
The US Breast Imaging Systems Market (2011 and 2016E)
2011 2018E
US$Million
2011 2016E
US$Billion
2011
2018E
US$ Million

5. The healthcare industry is fiercely competitive and characterized by incessant change and improvements
in technology….
The global market for breast cancer predictive diagnostic and drug technologies was valued at US$.........billion in 2011. The very number is expected
to reach nearly US$...........billion in 2016, at a five-year CAGR of ………..%.
In the field of breast cancer, the contention is mainly characterized by the range of agents, running the gamut from targeted therapies – exemplified by
the multi-tyrosine kinase inhibitors and receptor-targeted monoclonal antibodies – to broad-spectrum chemotherapeutic drugs.
Some of the well established companies enjoy significant competitive advantages over other domestic and small players on the basis of the below
mentioned factors:
-Significantly superior name recognition
-Large and more established distribution networks
-Additional product lines, and the ability to offer rebates or bundle products to offer discounts or incentives to gain a competitive advantage
-Higher levels of automation and more substantial installed bases of such equipment
-Extensive research, development, sales, marketing, manufacturing and financial capabilities
-Better financial resources allowing them to continue to improve their technology in order to compete in an evolving industry
Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa
2011 2016E
US$Billion
Global Breast Cancer Predictive Diagnostic and Drug Technologies
(2011 and 2016E)

6. Table of Contents
1. Breast Cancer: Overview
1.1 Types of Breast Cancer
1.2 Risk Factors
1.3 Symptoms of Breast Cancer
1.4 Diagnosis and Treatment of Breast Cancer
1.4.1 Breast Cancer Screening and Diagnostic
Measures
1.4.2 Breast Cancer Treatment Regime
2. Market Size
2.1 Breast Cancer Statistics
-New Cases
-Estimated Deaths
2.2 Breast Cancer Market Structure
- Therapeutics Market
-Diagnostics Market
-Market Segmentation
2.2.1 Regional Breast Cancer Markets
-The US
-Brazil
-India
2.3 Breast Cancer Therapeutics Model
3. Market Dynamics
3.1 Industry Trends and Developments
3.1.1 Successive Clinical Trials and Product
Development
List of Charts & Tables
List of Charts
Types of Breast Cancer
Various Biopsy Methods
Global Oncology Sales (2009-2014E)
Breast Cancer Therapeutics Market (2011 and 2020E)
Global Breast Cancer Predictive Diagnostic and Drug Technologies (2011
and 2016E)
The US Beast Imaging Systems Market (2011 and 2016E)
India‟s Breast screening Market (2011 and 2018E)
Number of Cancer Cases Worldwide (2007-2011)
Global Breast Cancer Incidences (2010 & 2030E)
Growth in Worldwide Obese Population (2004-2012F)
Global Female Population, +45 Years (2008-2014F)
Global Spending on Medicines (2006-2016E)
Global Spending on Medicine Share by Region (2006-2016E)
The US Spending on Medicine (2007-2016E)
Japan‟s Spending on Medicine (2007-2016E)
Hologic‟s Revenue Share by Business Segment (2012)
Hologic‟s Revenues and Net Income (2008-2012)
Johnson & Johnson‟s Revenue Share by Business Segments (2012)
Johnson & Johnson‟s Revenues and Net Earnings (2008-2012)
Siemens AG‟s Revenue Share by Business Segments (2012)
Siemens AG‟s Revenues and Net Income (2008-2012)
List of Tables
Stages of Breast Cancer
New Cases of Breast Cancer and Estimated Deaths in America (2013E)
America‟s Female Breast Cancer Statistics (2013E)
Global Breast Cancer Market Size by Segment (2011 and 2016E)
Total US Tomosynthesis Market Opportunity
NeuVax/E75 (nelipepimut) Sales – Breast Cancer Market Size Model (2017E-
2020E)

7. 3.2 Growth Drivers
3.2.1 Increasing Prevalence of Cancer
3.2.2 Increasing Use of Tobacco and Alcohol
3.2.3 Expanding Obese Population
3.2.4 Rising Demand for Better Healthcare Options
3.2.5 Growing Female Population (+45 Years)
3.2.6 Higher Spending on Medicines
3.3 Challenges
3.3.1 Rising Costs of Treatment
3.3.2 Stringent Regulatory Measures
3.3.3 Adverse Effects of the Treatment
3.3.4 Mounting Price Pressure
4. Competitive Landscape
5. Company Profiles
5.1 Hologic, Inc.
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
-Focus on Research & Development
-Business Expansion via Strategic Acquisitions
5.2 Johnson & Johnson
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
-Research & Development Activities
-Financial Risk Minimization
5.3 Siemens AG
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
-Accelerating R&D Activities
-Focus on Healthcare Segment
List of Tables
Ganetespib Metastatic Breast Cancer Revenue Build in the US
(2016E-2020E)
Breast Cancer Drugs & Agents in Clinical Development
Estimated Cancer Cases in the US (2012)
Estimated Cancer Deaths in the US (2012)
Patients Worldwide Waiting for Better Treatment Options (2011)
FDA Regulation of Medical Devices
Comparison of Adjuvant Chemotherapy Tests in Breast Cancer
J&J‟s R&D Statistics (2011 & 2012)

8. Koncept Analytics
CS-36, Second Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
T. +91-120-4130959
C: +91-9811715635
vikas@konceptanalytics.com
Contact Us:
www.konceptanalytics.com
Vikas Gupta
BD Manager
These are abridged and sanitized sample pages from the comprehensive report on the “Global Breast Cancer Market ”. To
know more about this report or for any customized research requirement, please contact the following:
View Report Details